Stockreport

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., April 27, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company [Read more]